covid
Anakinra
Anakinra is a recombinant IL-1 inhibitor that is currently FDA approved for rheumatoid arthritis, cryopyrin-associated Periodic Syndromes, and Deficiency of IL-1 Receptor Antagonist.IL-1β is a pro-inflammatory cytokine, and in conjunction with other pro-inflammatory cytokines and interferon, can trigger hyperinflammation and ARDS which is often seen in severe COVID19. Throughout the pandemic, Anakinra has been evaluated […]
nirmatrelvir
Nirmatrelvir/Ritonavir Recommendation 1: In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within five days of symptom onset rather than no nirmatrelvir/ritonavir. (Conditional recommendation†, Low certainty of evidence) Remarks: • Patients’ medications need to be screened for serious drug interactions • Dosing based […]
Tocilizumab
Tocilizumab Tocilizumab, a monoclonal anti-IL-6-receptor blocking antibody, has been proposed as a therapeutic agent to mitigate hyperinflammation associated with COVID-19. Tocilizumab is FDA-approved for various rheumatologic conditions as well as cytokine release syndrome associated with CAR-T cell therapy. Why are are interleukin-6 (IL-6) receptor antagonists considered for treatment? Some patients with COVID-19 develop a hyperinflammatory […]
Related lists
Hospital Lists